D030016E14Rik Activators
Trappc11, a member of the trafficking protein particle complex, is predicted to play a pivotal role in various cellular processes, including the constitutive secretory pathway, endoplasmic reticulum to Golgi vesicle-mediated transport, and the regulation of protein complex stability. Positioned upstream of vesicle-mediated transport and located in the Golgi apparatus, Trappc11 is implicated in the TRAPP complex, with its human ortholog TRAPPC11 linked to autosomal recessive limb-girdle muscular dystrophy type 2S.
Activation of Trappc11 involves a complex interplay of molecular mechanisms influenced by various chemical activators. Indirect activation is achieved through disrupting the constitutive secretory pathway and endoplasmic reticulum to Golgi vesicle-mediated transport. Chemicals targeting key players such as GBF1, Sar1, ARF1, and the Sec7 domain impair vesicle formation, stimulating Trappc11 activity. Additionally, inhibitors of N-glycosylation, cholesterol transport, Rho-associated protein kinase, protein synthesis, PERK, Rac1, and MEK1 indirectly activate Trappc11 by altering cellular processes and promoting its involvement in the constitutive secretory pathway and the regulation of protein complex stability. This detailed activation mechanism sheds light on the versatility of Trappc11 in responding to diverse intracellular signals and maintaining cellular homeostasis. The comprehensive understanding of these intricate regulatory pathways contributes not only to our knowledge of Trappc11 function but also opens avenues for exploring its implications in broader cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A, a GBF1 Inhibitor, indirectly activates Trappc11 by disrupting the constitutive secretory pathway. Inhibition of GBF1, a guanine nucleotide exchange factor, leads to impaired vesicle formation, stimulating Trappc11 activity in endoplasmic reticulum to Golgi transport. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A, an ARF1 Inhibitor, indirectly activates Trappc11 by disrupting vesicle-mediated transport. Inhibition of ARF1, a GTPase involved in vesicle budding, leads to impaired trafficking and stimulates Trappc11 participation in maintaining protein complex stability. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1, a Sec7 Domain Inhibitor, indirectly activates Trappc11 by disrupting endoplasmic reticulum to Golgi vesicle-mediated transport. Inhibition of the Sec7 domain hinders vesicle formation, enhancing Trappc11 engagement in the constitutive secretory pathway and protein complex stability. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3, a Sec7 Domain Inhibitor, indirectly activates Trappc11 by disrupting endoplasmic reticulum to Golgi vesicle-mediated transport. Inhibition of the Sec7 domain hinders vesicle formation, promoting Trappc11 involvement in the constitutive secretory pathway and protein complex stability. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin, an N-glycosylation Inhibitor, indirectly activates Trappc11 by influencing the endoplasmic reticulum to Golgi transport. Inhibition of N-glycosylation disrupts protein folding and trafficking, stimulating Trappc11 participation in maintaining protein complex stability. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
U18666A, a Cholesterol Transport Inhibitor, indirectly activates Trappc11 by disrupting endoplasmic reticulum to Golgi vesicle-mediated transport. Inhibition of cholesterol transport alters membrane dynamics, promoting Trappc11 involvement in the constitutive secretory pathway and protein stability. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a Rho-Associated Protein Kinase Inhibitor, indirectly activates Trappc11 by influencing the endoplasmic reticulum to Golgi transport. Inhibition of ROCK alters cytoskeletal dynamics, promoting Trappc11 involvement in the constitutive secretory pathway and protein complex stability. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin, a Protein Synthesis Inhibitor, indirectly activates Trappc11 by disrupting endoplasmic reticulum to Golgi vesicle-mediated transport. Inhibition of protein synthesis alters ER stress response, promoting Trappc11 participation in maintaining protein complex stability. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074, a MEK1 Inhibitor, indirectly activates Trappc11 by influencing the endoplasmic reticulum to Golgi transport. Inhibition of MEK1 alters the MAPK pathway, promoting Trappc11 involvement in the constitutive secretory pathway and regulation of protein complex stability. | ||||||